Last reviewed · How we verify

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 — Competitive Intelligence Brief

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 (CYD Dengue Vaccine Serotypes 1, 2, 3, and 4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 2 vaccine Dengue virus envelope proteins (E proteins) Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 (CYD Dengue Vaccine Serotypes 1, 2, 3, and 4) — Sanofi Pasteur, a Sanofi Company. The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 TARGET CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 Sanofi Pasteur, a Sanofi Company phase 2 vaccine Dengue virus envelope proteins (E proteins)
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
Meningococcal B (Bexsero) Meningococcal B (Bexsero) University of Sao Paulo General Hospital marketed Recombinant protein vaccine Meningococcal serogroup B surface antigens (recombinant Neisseria meningitidis proteins)
Fluvirin(TIVf) Fluvirin(TIVf) Novartis marketed Inactivated influenza vaccine
Flu Vaccine (Year 1) Flu Vaccine (Year 1) The Jackson Laboratory marketed vaccine
FluMist trivalent (2015-2016) FluMist trivalent (2015-2016) MedImmune LLC marketed Live attenuated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 — Competitive Intelligence Brief. https://druglandscape.com/ci/cyd-dengue-vaccine-serotypes-1-2-3-and-4. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: